The targeting of nanocarriers not only enhances the bioavailability of drugs at the lesion site but also effectively avoids acute and chronic metabolic toxicity (such as hyperglycemia) caused by extensive inhibition of the PI3K pathway in traditional treatments by limiting system exposure. This evidence concerns the gene PIK3CA and Hyperglycemia.